Clinical Trial on the Effects of Caffeine and Taurine From Energy Drinks (EDs) to Parameters of the Cardiovascular System in Humans
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01421979 |
Recruitment Status :
Completed
First Posted : August 23, 2011
Last Update Posted : February 5, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cardiovascular Risk | Dietary Supplement: Energy Drink, Taurine, Caffeine | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 38 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Prevention |
Study Start Date : | April 2011 |
Actual Primary Completion Date : | August 2013 |
Actual Study Completion Date : | August 2013 |

Arm | Intervention/treatment |
---|---|
Experimental: exposure under sleep deprivation
Examination of the effects of EDs in combination with alcohol consumption and sleep deprivation.
|
Dietary Supplement: Energy Drink, Taurine, Caffeine |
Experimental: Exercise after consumption
Examination of the effects of EDs in combination with alcohol consumption and exercise.
|
Dietary Supplement: Energy Drink, Taurine, Caffeine |
- Heart-rate-variability (HRV) [ Time Frame: during 24 hours ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 25 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- written informed consent
- healthy (no acute or chronic desease)
- BMI 20,0 - 25,9 kg/m2
- moderate and non-regular consumption of alcohol, EDs and coffee
Exclusion Criteria:
- pregnancy
- regular medication (oral contraceptives permitted)
- hypertension and other deseases of the cardiovascular system
- liver-deseases
- psychiatric deseases
- epilepsy
- other relevant deseases
- (former) alcoholics
- non-compliance to the study-protocol
- simultaneous participation in another clinical trial
- retraction of the written informed consent

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01421979
Germany | |
University of Hohenheim | |
Stuttgart, Baden-Württemberg, Germany, 70593 |
Responsible Party: | University of Hohenheim |
ClinicalTrials.gov Identifier: | NCT01421979 |
Other Study ID Numbers: |
ED2011 |
First Posted: | August 23, 2011 Key Record Dates |
Last Update Posted: | February 5, 2015 |
Last Verified: | February 2015 |
Caffeine Central Nervous System Stimulants Physiological Effects of Drugs Phosphodiesterase Inhibitors Enzyme Inhibitors |
Molecular Mechanisms of Pharmacological Action Purinergic P1 Receptor Antagonists Purinergic Antagonists Purinergic Agents Neurotransmitter Agents |